



Recombinant *H. suspectum* Exenatide (DAG3451)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	Recombinant Exenatide
Species	<i>H. suspectum</i>
Purity	> 96.0% as determined by SDS PAGE and HPLC analyses.
Conjugate	Unconjugated
Format	Lyophilized from a filtered solution in 20 mM PBS, pH 7.0 + 4% mannitol.
Preservative	None
Storage	2-8°C short term, -20°C long term

BACKGROUND

Introduction	Exenatide (INN, marketed as Byetta, Bydureon) is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication approved in April 2005 for the treatment of diabetes mellitus type 2. It belongs to the group of incretin mimetics and is manufactured by Amylin Pharmaceuticals. Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day. A once-weekly injection has been approved as of January 27, 2012 under the trademark Bydureon
Keywords	Exenatide; INN; glucagon-like peptide-1 agonist; GLP-1 agonist; exendin-4; glucagon-like peptide-1; GLP-1